Goodwin Advises GENFIT on Non-Dilutive Royalty Financing Agreement for Up to Euros185 Million
February 01, 2025
February 01, 2025
BOSTON, Massachusetts, Feb. 1 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised GENFIT (Nasdaq and Euronext: GNFT) on a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to Euros185 million in exchange for a portion of the royalties on sales of Iqirvo(R) (elafibranor). The agreement with HCRx includes an upfront payment of Euros130 million and up to Euros55 million via two additional instalments of Euros30 m . . .
The Life Sciences team advised GENFIT (Nasdaq and Euronext: GNFT) on a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to Euros185 million in exchange for a portion of the royalties on sales of Iqirvo(R) (elafibranor). The agreement with HCRx includes an upfront payment of Euros130 million and up to Euros55 million via two additional instalments of Euros30 m . . .